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Association of insulin resistance with depression:
cross sectional findings from the British women’s heart
and health study
Debbie A Lawlor, George Davey Smith, Shah Ebrahim
A large cohort study of nearly 15 000 individuals
found that indicators of insulin sensitivity were associ-
ated with increased risk of suicide.1 The authors
assumed that insulin resistance was the key factor
responsible. Insulin resistance is a determinant of free
fatty acids in the blood, which are in turn important in
tryptophan metabolism and brain serotonin concen-
trations.2 3 Individuals who are insulin resistant may
therefore have higher serotonin concentrations and as
a result be less likely to be depressed.1 We know of no
previous study that has assessed the association
between insulin resistance and depression in humans.
Participants, methods and results
We assessed this association in a cross sectional analy-
sis of 4286 women aged 60-79 who were randomly
selected from general practitioners’ lists in 23 British
towns.4 We used the homoeostasis model assessment
method (HOMA score), derived from fasting insulin
and glucose concentrations to assess insulin resist-
ance.4 We used three indicators of depression: current
use of antidepressant medication, self report of ever
having received a diagnosis of depression from a
doctor, and the EQ5D mood question of the
EuroQOL.5 Participants brought all of their medica-
tions to an interview with a nurse. We used the British
National Formulary (www.bnf.org/) to code medica-
tions; “antidepressants” included any medication in
section 4.3. Participants whose response to the EQ5D
mood question was that they were “today feeling either
moderately or extremely anxious and/or depressed”
were coded as currently anxious or depressed.
We categorised women without diabetes into quar-
ters of HOMA score and added a fifth category of
women with diabetes. We estimated proportions of
women with depression for each of these HOMA score
and diabetes categories. We used multiple logistic
regression to assess the effect of insulin resistance on
depression, with adjustment for potential confounding
factors. In all analyses we used robust standard errors,
allowing for potential clustering between women from
the same town, to calculate confidence intervals and
P values.
The prevalence of depression decreased linearly
with increasing insulin resistance among women with-
out diabetes and then increased among women with
diabetes (figure). The age adjusted odds ratio (95%
confidence interval) of current antidepressant use per
increase in one category (quarters of the distribution)
of HOMA score among non-diabetic women was 0.86
(0.76 to 0.96, P = 0.01). Similar results for ever being
diagnosed with depression and reporting feeling
anxious or depressed were 0.84 (0.74 to 0.97,
P = 0.006) and 0.89 (0.79 to 0.99, P = 0.04). None of
these associations was altered by further adjustment
for waist:hip ratio, body mass index, smoking, alcohol
consumption, physical activity, and social class during
adulthood and childhood.
Comment
Insulin resistance is inversely associated with depres-
sion. Our results are consistent with a large prospective
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(a) Prevalence % (95% confidence interval) of use of antidepressant
medication against quarters of HOMA score (insulin resistance) and
diabetes among British women aged 60-79. (b) Prevalence % (95%
confidence interval) of a self report of ever being diagnosed by a
doctor with depression against quarters of HOMA score (insulin
resistance) and diabetes among British women aged 60-79. (c)
Prevalence % (95% confidence interval) of a self report of feeling
depressed or anxious against quarters of HOMA score (insulin
resistance) and diabetes among British women aged 60-79
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study in which indicators of insulin sensitivity were
associated with suicide risk.1 The explanation for the
reverse J shaped association seen when diabetes was
included as a fifth category alongside insulin resistance
may be due to patients with a clinical diagnosis of
diabetes developing depression as a result of this
diagnosis.
We based our assessment of depression on current
use of medication and self reports of past diagnoses
and current mood rather than clinical assessment with
international diagnostic criteria. However, the consist-
ency of our findings across the three different
assessments supports a causal association, and any
measurement error in our assessment of depression
would tend to dilute the results. Insulin resistance is
positively associated with diabetes and cardiovascular
disease, and we do not believe that our results should
be used to discourage appropriate interventions to
prevent and treat insulin resistance. Further, these are
novel findings and need to be replicated in other stud-
ies. However, if our findings are confirmed there may
be an indication for assessing depressive symptoms
among individuals receiving treatments that affect
insulin resistance, since depressive symptoms are often
disabling and could affect compliance with treatment
and quality of life.
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Drug points
Pulmonary embolism possibly associated with
olanzapine treatment
Inger Marie Waage, Ane Gedde-Dahl
Antipsychotic drugs have been associated with an increased
risk of venous thromboembolism.1 We report for the first
time the case of a patient who developed a pulmonary
embolism after starting treatment with olanzapine.
A 28 year old man was admitted to hospital due to
a psychotic disorder. Treatment with olanzapine (10 mg/
day) was started, and the dose was gradually increased to
30 mg/day. He also received levomepromazine (50 mg/
day), oxazepam (10 mg/day), and flunitrazepam (1 mg/
day). After 10 weeks, the patient complained of respiratory
pain and he had two episodes of haemoptysis. Clinical
examination showed no auscultatory findings, no
dyspnoea, no tachypnoea, no fever, and normal blood
pressure and heart rate. Blood analysis showed raised
concentrations of C reactive protein (113 mg/l (normal
range < 10 mg/l)), fibrinogen (6 g/l (2-4 g/l)), and
d-dimer (0.89 mg/l ( < 0.50 mg/l)). Spiral computed tom-
ography showed a pulmonary embolism in the left lower
lobe. Standard anticoagulant treatment was started, and
the patient recovered. Olanzapine was discontinued, and
his medication changed to quetiapine.
Recent reports suggest an association between cloza-
pine and venous thromboembolic events.2–5 However,
thromboembolic complications have not previously been
described in patients taking olanzapine. The sedating
effects as well as the weight gain associated with this anti-
psychotic treatment can lead to a more sedentary lifestyle,
thus creating predisposing conditions for venous throm-
bosis. In this case, the patient was overweight (body mass
index 28.5), but his weight had not substantially changed
since starting to take olanzapine. He was otherwise
healthy, and his level of physical activity was normal. Tests
for possible coagulation disorders—including tests for
antiphospholipid antibodies (immunoglobulin lupus anti-
coagulants and anticardiolipin antibodies), mutation of
the methylenetetrahydrofolate reductase C677T thermo-
labile variant, prothrombin G20210A mutation, activated
protein C resistance, protein C, protein S, antithrombin
III, and homocysteine—did not show any underlying risk
factors. This leaves the question of the medication’s possi-
ble direct causal effect.
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